Company Name
Drug
Event
Outcome
Details
United Therapeutics Corp
(UTHR)
Tyvaso DPI (Resubmitted NDA)
May 2022
FDA decision on Tyvaso DPI for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease
FDA approves of Tyvaso DPI for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease on May 24, 2022-
MannKind Corp.
(MNKD)
Tyvaso DPI (Resubmitted NDA)
May 2022
FDA decision on Tyvaso DPI for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease
FDA approves Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease on May 24, 2022-
Eton Pharmaceuticals, Inc
(ETON)
Lamotrigine for Oral Suspension (NDA)
May 2022
FDA decision on Lamotrigine for the treatment of partial on-set seizures, primary generalized tonic-clonic seizures, and seizures of Lennox-Gastaut syndrome in patients two year of age and older
-
Read More Get Access to Premium FDA Calendar with RTT Biotech Investor.